Uncategorized

Capricor CEO won’t rule out legal action against FDA after negative adcomm

Capricor CEO won’t rule out legal action against FDA after negative adcomm

Published

on

After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version